• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the 'Rete Ematologica Pugliese E Basilicata'.

作者信息

Mele Giuseppe, Pastore Domenico, Di Renzo Nicola, Fragasso Alberto, Guarini Attilio, Mazza Patrizio, Musto Pellegrino, Pavone Vincenzo, Tarantini Giuseppe, Curci Paola, Falcone Antonietta Pia, Mele Anna, Miccolis Maria Rosanna, Palazzo Giulia, Palumbo Gaetano, Quinto Angela Maria, Reddiconto Giovanni, Rizzi Rita, Cascavilla Nicola, Specchia Giorgina, Capalbo Silvana Franca

机构信息

Haematology and BMT Unit, Ospedale Antonio Perrino, Brindisi, Italy.

Haematology and BMT Unit, Ospedale Vito Fazzi, Lecce, Italy.

出版信息

Leuk Lymphoma. 2019 Dec;60(14):3565-3568. doi: 10.1080/10428194.2019.1636989. Epub 2019 Jul 9.

DOI:10.1080/10428194.2019.1636989
PMID:31286780
Abstract
摘要

相似文献

1
Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the 'Rete Ematologica Pugliese E Basilicata'.泊马度胺联合低剂量地塞米松治疗复发难治性骨髓瘤的意大利真实世界经验：“普利亚大区和巴西利卡塔血液学网络”一项回顾性多中心研究的延长随访
Leuk Lymphoma. 2019 Dec;60(14):3565-3568. doi: 10.1080/10428194.2019.1636989. Epub 2019 Jul 9.
2
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese".来那度胺联合地塞米松治疗复发性和难治性多发性骨髓瘤的“真实世界”结局：“普利亚血液学网络”回顾性多中心研究的扩展随访。
Leuk Res. 2015 Mar;39(3):279-83. doi: 10.1016/j.leukres.2014.12.007. Epub 2014 Dec 23.
3
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.泊马度胺联合低剂量地塞米松与高剂量地塞米松单独用于治疗复发和难治性多发性骨髓瘤（MM-003）患者：一项随机、开放标签、3 期试验。
Lancet Oncol. 2013 Oct;14(11):1055-1066. doi: 10.1016/S1470-2045(13)70380-2. Epub 2013 Sep 3.
4
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.来那度胺治疗后复发或难治性多发性骨髓瘤患者的泊马度胺、硼替佐米和地塞米松治疗（OPTIMISMM）：一项随机、开放标签、3 期试验。
Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13.
5
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.依洛珠单抗联合泊马度胺和地塞米松治疗复发/难治性多发性骨髓瘤：在对照临床试验之外，对 321 例多中心回顾性真实世界经验的扩展随访。
Hematol Oncol. 2024 Jul;42(4):e3290. doi: 10.1002/hon.3290.
6
Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma.泊马度胺联合低剂量地塞米松对比高剂量地塞米松治疗复发和/或难治性多发性骨髓瘤的MM-003试验中的健康相关生活质量
Haematologica. 2015 Feb;100(2):e63-7. doi: 10.3324/haematol.2014.112557. Epub 2014 Nov 25.
7
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.泊马度胺、硼替佐米和地塞米松治疗来那度胺预处理的多发性骨髓瘤（OPTIMISMM）：首次复发时的既往治疗结果。
Leukemia. 2021 Jun;35(6):1722-1731. doi: 10.1038/s41375-020-01021-3. Epub 2020 Sep 7.
8
Intra-patient dose escalation of panobinostat in patients with relapsed/refractory multiple myeloma.复发/难治性多发性骨髓瘤患者中帕比司他的患者内剂量递增
Leuk Lymphoma. 2018 May;59(5):1277-1278. doi: 10.1080/10428194.2017.1372579. Epub 2017 Sep 6.
9
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.依沙佐米联合泊马度胺和低剂量地塞米松与泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤患者（ICARIA-MM）：一项随机、多中心、开放性、3 期研究。
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
10
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.在有肾功能损害的复发/难治性多发性骨髓瘤患者中，伊沙妥昔单抗联合泊马度胺和地塞米松：ICARIA-MM 亚组分析。
Leukemia. 2021 Feb;35(2):562-572. doi: 10.1038/s41375-020-0868-z. Epub 2020 May 23.

引用本文的文献

1
Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results.多发性骨髓瘤患者临床试验之外：真实世界结果的批判性综述
Front Oncol. 2022 May 11;12:844779. doi: 10.3389/fonc.2022.844779. eCollection 2022.
2
Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.泊马度胺联合地塞米松治疗复发或难治性多发性骨髓瘤患者：非干预性研究 POSEIDON 的最终结果及其与关键性 3 期临床试验的比较。
Eur J Haematol. 2022 Feb;108(2):133-144. doi: 10.1111/ejh.13719. Epub 2021 Nov 15.
3
Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan.
泊马度胺和地塞米松在真实临床环境中对复发或难治性多发性骨髓瘤有效：台湾一项多中心回顾性研究
Front Oncol. 2021 May 28;11:695410. doi: 10.3389/fonc.2021.695410. eCollection 2021.
4
Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study.泊马度胺联合低剂量地塞米松治疗复发/难治性多发性骨髓瘤患者：真实世界“POWERFUL”研究结果
J Clin Med. 2021 Apr 5;10(7):1509. doi: 10.3390/jcm10071509.
5
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.泊马度胺和地塞米松长期疾病控制对复发/难治性多发性骨髓瘤患者的临床益处
J Clin Med. 2019 Oct 16;8(10):1695. doi: 10.3390/jcm8101695.